Access AccuTnl+3 troponin I assay regulatory update

The U.K.'s NICE issued draft guidance recommending the Elecsys Troponin T high-sensitive assay from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) and the Architect Stat High Sensitive Troponin-I assay from Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.) for the early rule out of non-ST-segment elevation myocardial infarction (NSTEMI) in people presenting to an emergency department with chest pain and suspected acute coronary syndrome. NICE recommended the Access AccuTnl+3 troponin I assay from Danaher's Beckman Coulter Inc. subsidiary for research-use only in the indication due to a lack of evidence of its diagnostic accuracy. Comments on the guidance are due June 10, with a second committee meeting scheduled for June 24. ...